1 month After Plunging -30.17% in 4 Weeks, Here’s Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) Zacks

The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Earnings · Wall Street